Research programme: type 2 diabetes mellitus therapeutics - Mochida

Drug Profile

Research programme: type 2 diabetes mellitus therapeutics - Mochida

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mochida Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in Japan
  • 15 May 2015 Research programme: type 2 diabetes mellitus therapeutics - Mochida is available for licensing in World as of 15 May 2015. http://www.mochida.co.jp/english/business/licensing.html
  • 15 May 2015 Type-2 diabetes mellitus therapeutics are no longer licensed to Merck worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top